Kornimate/medical-research-clean huggingface dataset:
brexpiprazole (opc-34712) as an adjunctive treatment in active adults, 18 to 35 years old, with major depressive disorder who are in a school or work environment

Conditions: MDD

Summary: to investigate the efficacy and safety of flexibly dosed adjunctive brexpiprazole treatment in active adults with mdd, 18 to 35 years old, who are experiencing an inadequate selective serotonin reuptake inhibitor (ssri)/serotonin norepinephrine reuptake inhibitor (snri) response in a school or work environment.


Eligibility criteria:
main inclusion criteria: have a diagnosis of a single or recurrent, nonpsychotic episode of mdd as defined by the diagnostic and statistical manual of mental disorders, fourth edition, text revision (dsm-iv-tr) and confirmed by both the mini international neuropsychiatric interview (m.i.n.i.) and an adequate clinical psychiatric evaluation. have a treatment history of an inadequate adt response to at least 1 adt (but not \> 3) for the current episode. have received a single, trial-approved, ssri or snri at an adequate dose for ≥ 6 weeks prior to screening. are 18 to 35 years old at the time of consent (inclusive, and outpatients only). are (and will be) working 20 hours or more per week or a student taking 6 credit hours or more during the trial period, however minor deviations from the "part-time" concept may be acceptable on a case-by-case basis based on approval of the medical monitor. have a hamilton depression rating scale (ham-d)- 17-item total score ≥ 18 at screening and baseline. have a sheehan disability scale (sds) 3-item mean score ≥ 5 at baseline. main exclusion criteria: subjects with any of the following current axis i dsm-iv-tr diagnoses: delirium, dementia, amnestic, or other cognitive disorders; schizophrenia, schizoaffective disorder, or other psychotic disorders; bipolar i disorder, bipolar ii disorder, or bipolar disorder not otherwise specified (nos); eating disorders (including anorexia nervosa or bulimia); obsessive compulsive disorder; panic disorder; post-traumatic stress disorder; and attention deficit hyperactivity disorder. subjects with any of the following current axis ii dsm-iv-tr diagnoses: borderline, antisocial, paranoid, schizoid, schizotypal or histrionic personality disorders, or mental retardation.

Keywords: schizophrenia major depressive disorder anxiety symptoms school, work environment mental disorders psychotic disorders antipsychotic
effects of hyperbaric oxygen therapy in autistic children: a pilot study

Conditions: Autism; Oxidative Stress; Inflammation

Summary: autism is a neurodevelopmental disorder that currently affects as many as 1 out of 166 children in the united states. autism is considered by many to be a permanent condition with little hope for improvement. treatment for autism is centered on special schooling and behavioral therapy; medical science currently has little to offer. recent research has discovered that some autistic individuals have decreased blood flow to the brain, evidence of inflammation in the brain, and increased markers of oxidative stress. multiple independent single photon emission computed tomography (spect) and positron emission tomography (pet) research studies have revealed hypoperfusion to several areas of the autistic brain, most notably the temporal regions and areas specifically related to language comprehension and auditory processing. several studies show that diminished blood flow to these areas correlates with many of the clinical features associated with autism including repetitive, self-stimulatory and stereotypical behaviors, and impairments in communication, sensory perception, and social interaction. hyperbaric oxygen therapy (hbot) has been used with clinical success in several cerebral hypoperfusion syndromes including cerebral palsy, fetal alcohol syndrome, closed head injury, and stroke. hbot can compensate for decreased blood flow by increasing the oxygen content of plasma and body tissues and can even normalize oxygen levels in ischemic tissue. in addition, animal studies have shown that hbot has potent anti-inflammatory effects and reduces oxidative stress. furthermore, recent evidence demonstrates that hbot mobilizes stem cells from human bone marrow which may aid recovery in neurodegenerative diseases. based upon these findings, it is hypothesized that hbot will improve symptoms in autistic individuals. the purpose of this study is to determine if hbot improves clinical outcomes in children with autism. the study will also determine if hbot changes markers of inflammation and oxidative stress in autistic children.


Eligibility criteria:
inclusion criteria: * children diagnosed with autism spectrum disorder exclusion criteria: * seizures not controlled by medicine * inability to ventilate ears
manage your workingnegative thoughts through hypnosis

Conditions: Stress; Stress Disorders

Summary: medical doctor generally are exposed to several risks and pressures, it is not a case that several meta-analyses have shown high stress and anxiety level in these workers. stress management represents a very important topic. being a doctor means dealing with continous effort and arousal management to provide the best treatment through executive functions capacity. this is particularly true for younger medical trainees; that have also to learn how to deal with failure and the curve of learning. hypnosis has been shown to be very effective at modulating executive functions and sympathovagal balance, with large effect in post traumatic stress disease (ptsd), anxiety and executive function modulation. therefore, this study aim to investigate if hypnosis could be beneficial among medical trainees for managing negative thoughts related to work.

stress and anxiety are very important issues in medical training. several methods have been applied, from psychotherapy to biofeedback, but the physiological component usually have been dismissed. training medical trainees to manage their physiological activity through hypnosis can probably transfer practical results, i.e. increased wellbeing, modulation of the working energy and the transfer from planning to properly execution. to obtain this results after a basal evaluation of physiological data (hr; heart rate, hrv, heart rate variability, eda; electrodermal activity, and scr; skin conductance responses) stress and of anxiety levels, , with pss-10 scale, vas stress, vas anxiety and tower of london test ( tol-r), participants will recollect a negative memory for 3 minutes to monitor their response. after that a brief session of hypnosis will be performed with positive memories being recollected while all physiological data will be monitored. then participants will be subjected again to the negative memory task end at the end of the session the same test of the basal evaluation will be carried out.

Eligibility criteria:
inclusion criteria: * age \> 18 years old, * being medical doctor or at first year of residency in anesthesiology * obtained written informed consent exclusion criteria: * neurological issues affecting stress responses * diabetes * cardiovascular conditions (i.e., hypertension, orthostatic hypotension etc) * being under psychiatric medications * psychological or psychiatric diseases

Keywords: stress disorder hypnosis
rapid diagnosis and prognosis recognition of imaging and biomarkers in mild to moderate traumatic brain injury

Conditions: MTBI - Mild Traumatic Brain Injury; Moderate Traumatic Brain Injury

Summary: the investigators will carry out multi-center and large sample research based on the chinese population, screen the optimal diagnostic and prognosis recognition biomarkers and analyze the diagnostic critical cutoff values in patients with mild to moderate traumatic brain injury, so as to provide a substantial basis for clinical diagnosis and prognosis recognition.

traumatic brain injury (tbi) is a complex disorder that comprises a spectrum of intracranial pathologies, many of which present diagnostic challenges. detection of intracranial injuries after tbi relies on head ct, which is overused and resource intensive. prior studies have shown the potential for blood-based brain injury biomarkers to predict the absence of intracranial injury after tbi and aid in reducing unnecessary head ct use. furthermore, plasma biomarker concentrations in the acute phase after tbi identified patients with a suspected tbi and normal head ct who had detectable pathology on mri. however, most of the current studies are based on the european and american population, and whether the research results are applicable to the chinese population remains to be studied. therefore, the investigators will carry out multi-center and large sample research based on the chinese population, screen the optimal diagnostic and prognosis recognition biomarkers and analyze the diagnostic critical cutoff values, so as to provide a substantial basis for clinical diagnosis and prognosis recognition.

Eligibility criteria:
inclusion criteria: * age 18-75 years at time of recruitment. * glasgow coma scale (gcs) score of 9-15 at the time of informed consent. * non-penetrating tbi resulting from an external force. * diagnosed within 1 week after onset of tbi. * provision of informed written consent. exclusion criteria: * acute suspected stroke, neurosurgery, stroke or tia within the last 30 days. * neurodegenerative disease or other neurological disorder including dementia, parkinson's disease, multiple sclerosis, seizure disorder, brain tumors. * a history of a previous brain injury, or a history of concurrent substance or alcohol abuse; * the manifestation of tbi caused by medications, alcohol, drugs for other injuries (such as systemic injuries, facial injuries, or intubation). * pregnancy or breastfeeding. * patients with contraindications to mri scanning (such as patients with metal implants in their bodies, cardiac pacemakers, dentures, etc.) * participation in a clinical research study with potential to affect the results of this study

Keywords: mild to moderate traumatic brain injury biomarkers magnetic resonance image ct diagnosis prognostic identification
evaluation of agn-150998 in exudative age-related macular degeneration (amd)

Conditions: Age-related Macular Degeneration

Summary: this study is conducted in 3 stages. stage 1 is an open-label, dose-escalation assessment of the safety of agn-150998 administered as a single intravitreal injection to patients with advanced exudative age-related macular degeneration (amd). stage 2 and stage 3 are randomized, double-masked, comparisons of the safety and treatment effects on retinal edema and best-corrected visual acuity (bcva) of agn-150998 and ranibizumab in treatment-naive patients with exudative amd. study medication is administered as needed in stage 2 and with a fixed-dosing schedule in stage 3. the study objectives are (1) to identify the highest tolerated dose of agn-150998, (2) to assess the safety and duration of treatment effects on retinal edema and bcva, and (3) to characterize the systemic pharmacokinetic profile of agn-150998.


Eligibility criteria:
inclusion criteria: * exudative age-related macular degeneration * best-corrected visual acuity between 20/32 and 20/320 in the study eye exclusion criteria: * near-sightedness of 8 diopters or more * uncontrolled glaucoma in the study eye * cataract surgery or lasik within the last 3 months * any active ocular infection or inflammation
safety and efficacy of pd-1 inhibitors in patients with liver transplant

Conditions: Hepatocellular Carcinoma; Liver Transplantation

Summary: this is a perspective clinical study to assess the safety and efficacy of pd-1 inhibitors in patients with lt. eligible patients have recurrent or metastatic cancer after lt, are not amenable to, or refractory after, locoregional therapy or to a curative treatment approach (eg, surgery, or ablation) and have previously been treated with sorafenib or other targeted therapy, either intolerant to this treatment or show radiographic progression after treatment. biopsy is needed to exclude patients with positive allograft pd-l1 expression.


Eligibility criteria:
inclusion criteria: 1. patients with recurrence or metastases hepatocellular carcinoma after liver transplantation that not suitable for surgical resection and local treatments such as radiofrequency ablation, transcatheter arterial embolization and radiotherapy, been treated with sorafenib or other targeted therapy and are either intolerant to this treatment or show radiographic progression after treatment. 2. age 18-70 years old, male or female 3. biopsy shows negative allograft pd-l1 expression 4. child-pugh score ≤ 6 points (child-pugh a) 5. estimated postoperative survival time ≥ 12 weeks 6. ecog score 0-1 points 7. laboratory test indicators: white blood cells ≥ 3.0 × 109 / l, platelets ≥ 80 × 109 / l, hemoglobin ≥ 100g / l; total bilirubin ≤ 2.5 times the upper limit of normal, transaminase (ast, alt) ≤ 2.5 times upper limit of normal value, serum creatinine ≤ 1.5 times normal upper limit 8. have sufficient understanding and voluntarily sign informed consent to participate in clinical research exclusion criteria: 1. biopsy shows positive allograft pd-l1 expression 2. severe allergic reactions to other monoclonal antibodies 3. have any history of active autoimmune diseases or autoimmune diseases 4. the presence of active infection with hepatitis b or hepatitis c virus 5. severe cardiopulmonary dysfunction patients, have high blood pressure and blood pressure can not be controlled with drugs, unstable coronary artery disease (uncontrollable arrhythmia, unstable angina), non-compensatory congestive heart failure, within 6 months myocardial infarction

Keywords: checkpoint inhibitor immunotherapy
use of fibrin sealant patch for vein anastomosis during deceased donor liver transplantation- randomized clinical trial

Conditions: Liver Transplant; Complications

Summary: the study aims to evaluate the effect of the hemostatic matrix with fibrinogen and thrombin (tachosil®) on vena cava inferior anastomoses during liver transplantation from a deceased donor. the research comprises two groups: an experimental cohort with patients receiving a hemostatic matrix of fibrinogen and thrombin on the anastomotic line of the inferior vena cava, and a control cohort utilizing hemostasis without matrix sealent. the study involves a total of 170 participants, evenly distributed with 85 patients in each group.

studies have shown that materials containing fibrin shorten the time to hemostasis in the case of planned liver resection, but did not show a significant effect on the occurrence of postoperative bleeding. the aim of the study is to supplement knowledge about hemostatic matrices in liver transplantation, which will be used for the inferior vena cava anastomosis. the study aims to evaluate the effect of the hemostatic matrix with fibrinogen and thrombin (tachosil®) on vena cava inferior anastomoses during liver transplantation from a deceased donor. the research comprises two groups: an experimental cohort with patients receiving a hemostatic matrix of fibrinogen and thrombin on the anastomotic line of the inferior vena cava, and a control cohort utilizing hemostasis without matrix sealent. the study involves a total of 170 participants, evenly distributed with 85 patients in each group.

Eligibility criteria:
inclusion criteria: * age over 18 * elective liver transplantation * informed consent to participate in the study exclusion criteria: -decision to use packing during liver transplantation (bail out strategy)

Keywords: tachosil liver transplantation vena cava inferior anastomosis fibrin sealant hemostasis
effects of musculoskeletal rehabilitation courses on work ability

Conditions: Musculoskeletal Diseases or Conditions; Musculoskeletal Disorders

Summary: the goal of this observational study is to learn about the effects of two different musculoskeletal rehabilitation programs in working-age people with musculoskeletal disorders. the main question it aims to answer is: do musculoskeletal rehabilitation programs a or b improve work ability in people with musculoskeletal disorders? participants starting in rehabilitation programs a and b will answer survey questions about their work ability and related factors three times: when starting, immediately after the rehabilitation ends, and 4 months after ending the rehabilitation. participants in study group c will answer the same questions during the same time period. researchers will compare participants in rehabilitation programs a and b to participants in group c, who have musculoskeletal disorders but will not participate in rehabilitation programs. the comparison is done to see if there are differences in the changes in work ability and related factors, such as pain or quality of life.


Eligibility criteria:
inclusion criteria: groups 1 ja 2: * diagnosed musculoskeletal disorder * 18 years or older * in employment, returning to work, studying, or receives rehabilitation subsidy * participating in either of the following: * kela's face-to-face musculoskeletal rehabilitation (a) * kela's musculoskeletal telerehabilitation (b) * willingness to participate in the study group 3 (controls): * diagnosed musculoskeletal disorder * 18 years or older * in employment, returning to work, studying, or receives rehabilitation subsidy * musculoskeletal symptoms have lasted at least 3 months and the person has participated in physiotherapy or self-rehabilitation without satisfactory results * willingness to participate in the study exclusion criteria: group 3 (controls): * current rehabilitation needs are related to post-treatment care or post-discharge rehabilitation. * acute or untreated substance use disorder * participating in or apply for kela's musculoskeletal rehabilitation services (a or b) during the next few months

Keywords: musculoskeletal diseases musculoskeletal disorders work ability rehabilitation telerehabilitation quality of life pain chronic pain musculoskeletal pain
histocompatibility leukocyte antigen (hla)-a*2402 restricted peptide vaccine therapy in patients with breast cancer

Conditions: Breast Cancer

Summary: the purpose of this study is to evaluate the safety and time to progression of hla-a\*2402 restricted epitope peptide ttk emulsified with montanide isa 51.

ttk has been identified as cancer specific molecules especially in breast cancer using genome-wide expression profile analysis by cdna microarray technique. we have determined the hla-a\*2402 restricted epitope peptide derived from this molecule and identified that this peptide significantly induces the effective tumor specific ctl response in vitro and vivo. according to these findings, in this trial, we evaluate the safety, immunological and clinical response of that peptide. patients will be vaccinated twice a week for 8 weeks. on each vaccination day, ttk-a24-567 peptide (1mg) mixed with montanide isa 51 will be administered by subcutaneous injection. repeated cycles of vaccine will be administered until patients develop progressive disease or unacceptable toxicity, whichever occurs first. in the phase i study, we evaluate the safety and tolerability of this peptide vaccine. in the following phase ii study, we evaluate the immunological and clinical response of this vaccine therapy.

Eligibility criteria:
inclusion criteria: * advanced or recurrent breast cancer * resistant against anthracycline-based and taxane-based chemotherapy or difficult to continue the chemotherapy due to intolerable side effect(s) * resistant against trastuzumab or difficult to continue it due to intolerable side effect(s) when her-2 is positive * ecog performance status 0-2 * life expectancy \> 3 months * hla-a\*2402 * laboratory values as follows * 2000/mm3\<wbc\<15000/mm3 * platelet count\>100000/mm3 * bilirubin \< 3.0mg/dl * asparate transaminase \< 150iu/l * alanine transaminase \< 150iu/l * creatinine \< 3.0mg/dl * able and willing to give valid written informed consent exclusion criteria: * pregnancy(woman of childbearing potential:refusal or inability to use effective means of contraception) * breastfeeding * active or uncontrolled infection * concurrent treatment with steroids or immunosuppressing agent * prior chemotherapy,radiation therapy, or immunotherapy within 4 weeks * uncontrolled brain and/or intraspinal * decision of unsuitableness by principal investigator or physician-in-charge

Keywords: hla-a*2402 peptide vaccine ttk
the ventilation during in-hospital cardiac arrest study

Conditions: Cardiac Arrest (CA); In-Hospital Cardiac Arrest; Heart Arrest

Summary: the goal of this prospective observational study is to learn how ventilation quality parameters during cardiopulmonary resuscitation (cpr) are associated with short-term survival following in-hospital cardiac arrest of adult patients. the main questions it aims to answer are: what ventilation volume during cpr is associated with the highest chance of return of spontaneous circulation (rosc)? what ventilation rate during cpr is associated with the highest chance of rosc? researchers will compare different levels of ventilation rates and volumes that are blindly measured during cpr to see how the observed rates and volumes are associated with survival outcomes and complications.


Eligibility criteria:
inclusion criteria: 1. in-hospital cardiac arrest 2. age ≥ 18 years 3. \>1minute of recorded ventilation data exclusion criteria: 1. documented do-not-attempt cardiopulmonary resuscitation order 2. invasive mechanical circulatory support at the time of the cardiac arrest

Keywords: prospective observational study ventilation manual ventilation cardiac arrest in-hospital cardiac arrest (ihca) bag-valve-mask (bvm) tidal volume ventilation rate intra-arrest ventilation cardiopulmonary ventilation (cpr) resuscitation adult
the effect of chest compression and ventilation coordination during cardiopulmonary resuscitation.

Conditions: Out-of-Hospital Cardiac Arrest; Sudden Cardiac Death

Summary: airway management and maintaining adequate ventilation during cardiopulmonary resuscitation (cpr) are important. the rule of 30:2 compression-to-ventilation ratios before endotracheal intubation and keeping 1 breath every 6-8 seconds with advanced airway are generally accepted according to 2010 advanced cardiac life support (acls) guideline. this recommendation emphasizes on the timing and frequency of ventilation during cpr. however, poor clinical evidence had been established concerning adequate volume, airway flow and pressure in each cycle. there are increasing evidence that hyperventilation during resuscitation reduces pulmonary venous return and, therefore, compromises cardiac output and circulation. another research reported that using high flow oxygen mask alone during basic life support (bls) results in better survival rate and overall outcome compared with conventional positive pressure ventilation. our study applies flowmeter to measure ventilation parameters as frequency, duration, exhaled volume and airway pressure on intubated patients who received artificial ventilation during cpr. the parameters will correlate with information from accelerometry and capnometry simultaneously during resuscitation. . investigators also focus on the influence of chest compression, which increases intra-thoracic pressure considerably. this effect may act against positive pressure ventilation and probably minimize the efficiency in each ventilation or circulation.. details about how to ventilate one patient during cpr include right timing, duration, adequate volume and coordination are in debate. unfortunately, current practice based on clinical guidelines emphasizes little on this issue. investigators are committed to refine contemporary practices and hopefully improve qualities of resuscitation. investigators proposed the hypothesis that coordinate chest compression and ventilation may minimize the increasement of airway pressure and improve the effect of circulation


Eligibility criteria:
inclusion criteria: * age \> 20 years old, \< 100 years old exclusion criteria: * trauma related out of hospital cardiac arrest

Keywords: cardiopulmonary resuscitation,ventilation